Last close As at 05/08/2026
EUR3.26
▲ 0.05 (1.56%)
Market capitalisation
EUR77m
Research: Healthcare
OSE Immunotherapeutics (OSE) has reported positive preclinical efficacy data for its novel monoclonal antibody therapy OSE-127 in B- and T-cell acute lymphoblastic leukaemia (ALL) disease models. OSE-127 was found to display efficacy signals as a monotherapy in 96% of B- and T-ALL patient-derived xenografts, which included samples from difficult-to-treat relapsed/refractory (r/r) patients. Additionally, details of OSE-127’s unique dual mechanism of action were elucidated, potentially providing differentiation over existing therapies. OSE-127 is being investigated in Phase II studies for the treatment of primary Sjögren’s syndrome and ulcerative colitis and while we acknowledge preclinical results may not translate into clinical utility, the latest data provide encouraging signs for the potential expansion of OSE-127 into additional indications. We continue to value OSE at €398.4m or €21.5 per share.
Written by
OSE Immunotherapeutics |
OSE-127 encouraging preclinical data in ALL |
Preclinical update |
Healthcare and biotech |
15 December 2022 |
Share price performance
Business description
Analysts
OSE Immunotherapeutics is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||||||||||||
OSE Immunotherapeutics (OSE) has reported positive preclinical efficacy data for its novel monoclonal antibody therapy OSE-127 in B- and T-cell acute lymphoblastic leukaemia (ALL) disease models. OSE-127 was found to display efficacy signals as a monotherapy in 96% of B- and T-ALL patient-derived xenografts, which included samples from difficult-to-treat relapsed/refractory (r/r) patients. Additionally, details of OSE-127’s unique dual mechanism of action were elucidated, potentially providing differentiation over existing therapies. OSE-127 is being investigated in Phase II studies for the treatment of primary Sjögren’s syndrome and ulcerative colitis and while we acknowledge preclinical results may not translate into clinical utility, the latest data provide encouraging signs for the potential expansion of OSE-127 into additional indications. We continue to value OSE at €398.4m or €21.5 per share.
Year end |
Revenue |
PBT* |
EPS* |
DPS |
DPS |
Yield |
12/20 |
10.4 |
(18.5) |
(1.02) |
0.0 |
N/A |
N/A |
12/21 |
26.3 |
(16.5) |
(0.89) |
0.0 |
N/A |
N/A |
12/22e |
16.0 |
(27.8) |
(1.28) |
0.0 |
N/A |
N/A |
12/23e |
0.0 |
(44.2) |
(2.42) |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Dysregulation and overexpression of the interleukin-7 receptor (IL7R) has been found to play a critical role in the development of T-ALL and B-ALL , providing an attractive therapeutic target for the development of new treatment modalities. In particular, T-ALL is highly aggressive and existing standard of care is often highly cytotoxic chemotherapy regimens, so there is a need to develop new therapeutics with improved safety profiles and efficacy in hard-to-treat r/r patients.
The preclinical study also revealed insights into OSE-127’s unique mechanism of action, acting as both a IL7R inhibitor and antibody-dependent cellular phagocytosis inducer. This dual mechanism may be contributing to OSE-127’s enhanced efficacy. Additionally, OSE-127 in combination with polychemotherapy (dexamethasone/vincristine/PEG-asparaginase) resulted in increased survival, with disease clearance in 56% of treated cases.
In our view, combination therapies will be critical for clinical breakthroughs in oncology, so we see this result as highly positive and it may help guide OSE-127’s clinical strategy in ALL.
|
|
Research: Healthcare
IRLAB Therapeutics has announced that the final patient has completed the treatment period and follow-up visit in its Phase IIb study investigating mesdopetam in the treatment of patients with Parkinson’s disease levodopa-induced dyskinesias (PD-LIDs). We see this as a significant milestone for the trial as IRLAB now looks to complete the data package following completion of the treatment period and to report top-line results in mid-January 2023. We had previously communicated that initial top-line readouts from the study would be disclosed around Q422. However, we do not see this as having any major impact on mesdopetam’s developmental timeline in PD-LIDs. We value IRLAB at SEK6.72bn or SEK129.8 per share.